Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Numinus Wellness Inc T.NUMI

Alternate Symbol(s):  NUMIF

Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.


TSX:NUMI - Post by User

Post by Adwarion Dec 29, 2020 10:50pm
243 Views
Post# 32194868

News Out: Closing of $17 million bought deal offering

News Out: Closing of $17 million bought deal offering

Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

V.NUMI 

Canada NewsWire 

Proceeds add to recently executed warrants and options of $8.9 million 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES 

VANCOUVER, BC Dec. 29, 2020 /CNW/ - Numinus Wellness Inc. (" Numinus " or the " Company ") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that it has closed its previously announced bought deal public offering (the " Offering ") of units (the " Units ") through Canaccord Genuity Corp. and Eight Capital (the " Underwriters ") pursuant to a short form prospectus dated December 21, 2020 

Numinus Wellness Inc. (CNW Group/Numinus Wellness Inc.)

Pursuant to the Offering, the Company issued 25,367,850 Units, on an underwritten basis, at the purchase price of $0.68 per Unit (the " Offering Price "), for aggregate gross proceeds to the Company of $17,250,138 , which includes the exercise, in full, by the Underwriters of the over-allotment option (the " Over-Allotment Option ") granted by the Company to purchase an additional 3,308,850 Units at the Offering Price. 

Each Unit consists of one common share of the Company (a " Common Share ") and one-half of one common share purchase warrant of the Company (each whole warrant, a " Warrant "). Each Warrant is exercisable to acquire one Common Share until December 29, 2022 at an exercise price of $0.90 per Common Share. 

In consideration for their services, the Company paid to the Underwriters a cash commission equal to 6% of the aggregate gross proceeds of the Offering in the amount of $1,035,008.28 , including gross process raised on exercise of the Over-Allotment Option, and issued to the Underwriters 1,522,071 compensation warrants (the " Compensation Warrants "). Each Compensation Warrant may be exercised to acquire one Common Share (each, a " Compensation Share ") at an exercise price of $0.68 per Compensation Share until December 29, 2022 

In addition, the Company paid a corporate finance fee (the " Corporate Finance Fee ") in the amount of $250,000 with 50% of the Corporate Finance Fee paid in cash and 50% of the Corporate Finance Fee paid in Common Shares (the " Corporate Finance Fee Shares ") at a deemed price of $0.68 per Corporate Finance Fee Share for a total of 183,824 Corporate Finance Fee Shares 

The Company intends to use the net proceeds of the Offering for clinic upgrades to prepare for clinical trials, laboratory upgrades, clinic acquisitions, research and development of medical protocols, and general working capital. 

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. 

In addition to the bought deal public offering, over the past 12 weeks, Numinus has received approximately $8.9 million in gross proceeds from the exercise of warrants and stock options. 

"This over-subscribed financing, along with the exercised warrants and options, not only strengthens our cash position, but clearly demonstrates confidence in our business model, our progress, and our growth prospects," said Payton Nyquvest , Founder, CEO, and Chair, Numinus. "We are closing off 2020 in a strong position with the financing topping off our recent exclusive Psilocybe harvest and extraction , our planned compassionate access trial of psilocybin , our partnership with MAPS for an MDMA compassionate access trial, our national expansion with the acquisition of Mindspace , and our successful lobbying of Health Canada resulting in its notice of intent to amend the Special Access Programme to include accessibility to psilocybin and MDMA . We are ready for a fast-paced year ahead, and I would like to use this opportunity to sincerely thank our supporters and to wish you all a healthy, safe and happy New Year." 

 

 


<< Previous
Bullboard Posts
Next >>